The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells
- 1 February 2003
- journal article
- Published by Springer Nature in Leukemia
- Vol. 17 (2) , 451-457
- https://doi.org/10.1038/sj.leu.2402832
Abstract
Mutations of the ras gene are among the most commonly identified transforming events in human cancers, including multiple myeloma. Farnesyltransferase inhibitors (FTI) were developed to prevent Ras processing and induce cancer cell death. Several FTIs are in phase II and one is in phase III clinical trials. Preclinically, most of the focus has been on solid tumors, and the effects of FTIs in multiple myeloma have not been investigated. In this study we examined the cytotoxic activity and inhibition of Ras processing in three myeloma cell lines with differing Ras mutation status. H929 cells with activated N-Ras were more sensitive to FTI-277 treatment than 8226 and U266 cells with activated K-Ras or wild-type Ras, respectively. A combination of FTI-277 and a geranylgeranyltransferase I inhibitor (GGTI)-2166 inhibited K-Ras processing and enhanced cell death in 8226 cells. U266 cells and Bcl-xL transfectants were equally sensitive to FTI-277 treatment. Similarly, 8226 cells selected for resistance to various chemotherapeutic agents, which resulted in either P-glycoprotein overexpression, altered topoisomerase II activity, or elevated glutathione levels, were equally sensitive to FTI-277. These preclinical studies suggest that prenylation inhibitors may represent new therapeutic agents for the treatment of refractory or drug-resistant multiple myeloma.Keywords
This publication has 16 references indexed in Scilit:
- The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell LinesExperimental Cell Research, 2001
- Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesExpert Opinion on Investigational Drugs, 2000
- Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalanBlood, 2000
- Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenograftsOncogene, 1998
- Multiple Myeloma: Increasing Evidence for a Multistep Transformation ProcessBlood, 1998
- Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell linesOncogene, 1997
- Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistanceInternational Journal of Cancer, 1996
- Ras oncogene mutation in multiple myeloma.The Journal of Experimental Medicine, 1989
- All ras proteins are polyisoprenylated but only some are palmitoylatedCell, 1989
- The p21 ras C-terminus is required for transformation and membrane associationNature, 1984